Clinical Research Directory
Browse clinical research sites, groups, and studies.
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Summary
This platform trial will evaluate various immunotherapy combinations given in the neo-adjuvant and adjuvant setting in patients with surgically resectable pancreatic ductal adenocarcinoma.
Official title: A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2016-03-28
Completion Date
2026-05-31
Last Updated
2025-12-03
Healthy Volunteers
No
Conditions
Interventions
Cyclophosphamide
200 mg/m2 IV
GVAX pancreatic cancer
5x10\^8 cells intradermal injection
Nivolumab
480 mg IV
Urelumab
8 mg IV
BMS-986253
2400 mg IV
Locations (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States